# RNN 2nd Gen Model Zoetis Inc. Pharmaceutical preparations

Stock predictor AI models:
Subscribe >> Deal exit on
July 22, 2020
Deal entry on
July 22, 2020
18.09%Expected margin
68.25% successful of 63 deals
$ 157.72 Last close price
at 05-aug-2020

ZTS

Model's trade recommendations No return for period yet

-6.47% Annual return

$38.77B Market Cap

β 0.97  

ZTS

Model (following trade recommendations)

ZTS

Underlying stock

S&P 500

Index
Return for period
14.56%
1.78%
52wk return 5.95%
30.47%
16.82%
52wk Range
92.66—157.72
2000.54—2399.63
Sortino ratio -0.28
Sharpe ratio -0.26
Norm. RMSE 15.43%
Downside risk 17.58%
Volatility 0.00%
  • 0.50 (0.63%) Div (Yield)
  • BUY Analysts consensus recommendation

Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services.

Industry sector: Medical

Sector classification: Pharmaceutical preparations

Deep Learning based analysis and prediction model for Zoetis Inc. (ZTS) stock is a 2nd Generation Non-linear Autoregressive (NAR) model based on the LSTM/GRU Recurrent Neural Network architecture.

Model is in the production pipeline since Oct. 22, 2015.

Market data for ZTS model training are being downloaded from the Quandl premium datasets on a daily basis.
Risks related to the novel coronavirus disease 2019 (COVID-19) caused by the virus named “SARS-CoV-2” are accounted for in this model in the form of the historical data coincided with outbreaks and other global events in the past used to train ML prediction model for ZTS.

Model is being retrained on a regular basis.

-->
Float 484M
P/E 30.50
Shares Outstanding 485M
% Held by Insiders 0.35%
% Held by Institutions 92.60%
EPS (last reported FY) $2.40
EPS (last reported Q) $0.75
EPS, estimated (last reported Q) $0.70
Total revenues $5 B
Net income $1 B